Trogocytic CD137 transfer causes an internalization of CD137 ligand on murine APCs leading to reduced T cell costimulation
- PMID: 25765680
- DOI: 10.1189/jlb.3A0213-079RRR
Trogocytic CD137 transfer causes an internalization of CD137 ligand on murine APCs leading to reduced T cell costimulation
Abstract
CD137 ligand (CD137L) is expressed on APCs and crosslinks CD137, a powerful costimulatory molecule on T cells during cognate interactions, and thereby greatly enhances immune responses. We report that CD137 can be transferred from activated T cells and from tumor cells that express CD137 to other cells via trogocytosis. This trogocytic transfer is independent of CD137L expression by the recipient cell. However, if CD137L is present on the recipient cell, the transferred CD137 binds to CD137L and the CD137-CD137L complex becomes internalized. The removal of CD137L from the surface of APCs lowers their ability to costimulate T cells, as evidenced by a reduced IFN-γ secretion. Removal of CD137L on APCs by trogocytic transfer of CD137 occurs within 1 h and requires cell-cell contact and the continuous presence of CD137-expressing cells. Bidirectional signaling exists for the CD137 receptor/ligand system, because CD137L also signals into APCs. We propose that the trogocytic transfer of CD137 from activated T cells to APCs and the subsequent removal of CD137L from APCs is a physiologic regulatory mechanism that limits immune activity. Furthermore, we hypothesize that the trogocytic transfer of CD137 occurs in cancers and quenches the activity of APCs, contributing to the cancer cells escaping immune surveillance. Taken together, our findings demonstrate that the trogocytic transfer of CD137 leads to an internalization of CD137L on APCs and a reduction in immune activity.
Keywords: IFN-γ; immune regulation.
© Society for Leukocyte Biology.
Similar articles
-
Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis.Cells. 2021 Feb 9;10(2):353. doi: 10.3390/cells10020353. Cells. 2021. PMID: 33572150 Free PMC article.
-
Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression.Cancer Res. 2013 Jan 15;73(2):652-61. doi: 10.1158/0008-5472.CAN-12-3849. Epub 2012 Nov 29. Cancer Res. 2013. PMID: 23204227
-
CD137 and CD137 ligand constitutively coexpressed on human T and B leukemia cells signal proliferation and survival.Int J Cancer. 2004 Jan 20;108(3):390-8. doi: 10.1002/ijc.11574. Int J Cancer. 2004. PMID: 14648705
-
The Progress of Investigating the CD137-CD137L Axis as a Potential Target for Systemic Lupus Erythematosus.Cells. 2019 Sep 6;8(9):1044. doi: 10.3390/cells8091044. Cells. 2019. PMID: 31500130 Free PMC article. Review.
-
CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses.Oncoimmunology. 2015 Nov 11;5(4):e1113367. doi: 10.1080/2162402X.2015.1113367. eCollection 2016 Apr. Oncoimmunology. 2015. PMID: 27141396 Free PMC article. Review.
Cited by
-
Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis.Cells. 2021 Feb 9;10(2):353. doi: 10.3390/cells10020353. Cells. 2021. PMID: 33572150 Free PMC article.
-
Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors.Cancer Immunol Immunother. 2022 Nov;71(11):2583-2596. doi: 10.1007/s00262-022-03183-8. Epub 2022 Mar 17. Cancer Immunol Immunother. 2022. PMID: 35299256 Free PMC article.
-
CD137L-DCs, Potent Immune-Stimulators-History, Characteristics, and Perspectives.Front Immunol. 2019 Oct 2;10:2216. doi: 10.3389/fimmu.2019.02216. eCollection 2019. Front Immunol. 2019. PMID: 31632390 Free PMC article. Review.
-
Ectopic CD137 expression by rhabdomyosarcoma provides selection advantages but allows immunotherapeutic targeting.Oncoimmunology. 2021 Feb 4;10(1):1877459. doi: 10.1080/2162402X.2021.1877459. Oncoimmunology. 2021. PMID: 33643694 Free PMC article.
-
Trogocytosis-Mediated Intracellular Signaling in CD4+ T Cells Drives TH2-Associated Effector Cytokine Production and Differentiation.J Immunol. 2019 May 15;202(10):2873-2887. doi: 10.4049/jimmunol.1801577. Epub 2019 Apr 8. J Immunol. 2019. PMID: 30962293 Free PMC article.
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous